225 related articles for article (PubMed ID: 1511458)
41. Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells.
Kikuchi T; Joki T; Abe T; Ohno T
J Immunother; 1999 May; 22(3):245-50. PubMed ID: 10335484
[TBL] [Abstract][Full Text] [Related]
42. Age related natural killer activity of peripheral blood lymphocytes from healthy subjects and cancer patients. A comparative in vitro study with interleukin-2.
Chakraborty A; Chakraborty NG; Chattopadhyay U
Tumori; 1994 Jun; 80(3):233-7. PubMed ID: 8053083
[TBL] [Abstract][Full Text] [Related]
43. Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2.
Kim R; Lafreniere R; Borkenhagen K; Bryant LD
Cancer Immunol Immunother; 1989; 30(5):283-8. PubMed ID: 2624921
[TBL] [Abstract][Full Text] [Related]
44. Human cytotoxic CD8+ T-lymphocyte clones engraft in severe combined immunodeficient (SCID) mice but show diminished function.
de Kroon JF; van Bergen CA; de Paus RA; Kluin-Nelemans HC; Willemze R; Falkenburg JH
J Immunother; 1997 Mar; 20(2):101-10. PubMed ID: 9087382
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
Maruyama T; Imai Y; Harada K; Okada T; Takano M; Ikeda Y; Toda G; Oka H; Osawa T
J Biol Response Mod; 1990 Aug; 9(4):378-86. PubMed ID: 2395003
[TBL] [Abstract][Full Text] [Related]
46. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
47. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
48. Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. Phenotypic and functional analysis of the peripheral blood mononuclear cells.
Fortis C; Ferrero E; Besana C; Biffi M; Heltai S; Galli L; Borri A; Schoenheit A; Rugarli C
Cancer Immunol Immunother; 1990; 32(3):161-6. PubMed ID: 2289209
[TBL] [Abstract][Full Text] [Related]
49. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells.
Mahvi DM; Carper SW; Storm FK; Teal SR; Sondel PM
Cancer Immunol Immunother; 1993 Aug; 37(3):181-6. PubMed ID: 8334681
[TBL] [Abstract][Full Text] [Related]
51. Lymphokine-activated effector cells: modulation of activity by cytokines.
Mehta S; Flanagan P; Blackinton D; Wanebo H
Lymphokine Cytokine Res; 1992 Apr; 11(2):73-7. PubMed ID: 1581419
[TBL] [Abstract][Full Text] [Related]
52. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
Stewart LS; Sewell HF; Thomson AW
Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
[TBL] [Abstract][Full Text] [Related]
53. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
54. The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.
Ozaki A; Nakano H; Minato K; Nakagawa K; Sasaki Y; Saijo N
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1055-60. PubMed ID: 3261691
[TBL] [Abstract][Full Text] [Related]
55. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
Kawakami K; Bloom ET
Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
[TBL] [Abstract][Full Text] [Related]
56. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
57. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.
Itoh K; Pellis NR; Balch CM
Cancer Immunol Immunother; 1989; 29(1):57-62. PubMed ID: 2785000
[TBL] [Abstract][Full Text] [Related]
58. Human recombinant interleukin-4 inhibits lymphokine-activated killer activity of sheep erythrocyte rosette-forming (E+) and -non-forming (E-) human lymphocytes.
Gerosa F; Tommasi M; Gerosa M; Tridente G
Int J Cancer; 1988 Dec; 42(6):902-5. PubMed ID: 3263954
[TBL] [Abstract][Full Text] [Related]
59. Effects of cyclosporin on C57BL/6 splenocytes before and after culture with high-dose recombinant interleukin-2: implications for immunosuppression with cyclosporin.
Sutherland F; Borkenhagen K; Temple L; Bryant LD; Lafreniere R
Cancer Immunol Immunother; 1990; 31(5):312-20. PubMed ID: 2376049
[TBL] [Abstract][Full Text] [Related]
60. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
Kawase I; Shirasaka T; Ikeda T; Hara H; Tanio Y; Watanabe M; Saito S; Masuno T; Kishimoto S; Yamamura Y
Jpn J Cancer Res; 1989 Nov; 80(11):1098-105. PubMed ID: 2481664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
